Danaher (DHR) shares fall as Q4 FCF comes in sharply below consensus
Get Alerts DHR Hot Sheet
EPS Growth %: +1.6%
Financial Fact:
Research and development expenses: -241.1M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Danaher (NYSE: DHR) reported Tuesday fourth-quarter sales and profit that exceeded the analyst expectations.
The company's sales reached $6.41 billion, surpassing the consensus estimate of $6.02 billion. Alongside this, Danaher reported an adjusted earnings per share (EPS) of $2.09, ahead of the consensus of $1.89.
However, the company's adjusted free cash flow, at $1.2 billion, fell short of the estimated $1.84 billion.
The stock fell 3.8% in the aftermath of the Q4 earnings report.
Looking ahead to the first quarter of 2024, Danaher anticipates a decrease in adjusted core revenue, expecting it to be down by “a high-single-digit percentage year-over-year.”
Rainer M. Blair, President and Chief Executive Officer, stated, "We delivered better-than-expected revenue in each of our segments in the fourth quarter—led by respiratory revenue at Cepheid. The combination of higher-than-expected revenues and our team's strong execution enabled us to exceed our margin and cash flow expectations in what remains a dynamic market environment.”
By Senad Karaahmetovic
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Samsara Inc (IOT) Tops Q2 EPS by 4c, Beats on Revenue; Offers Q3 Guidance
- Pepsi’s media strategy shift could create an ‘unexpected’ winner in media – BofA
Create E-mail Alert Related Categories
Corporate News, Earnings, Guidance, Hot List, Management Comments, Momentum MoversRelated Entities
Earnings, Senad KaraahmetovicSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share